FIELD: biotechnology.
SUBSTANCE: method comprises the following stages: preparing cells in the first set comprising at least 96 receivers, adding an agent at least to one receiver; incubating the agent with the cells, lysing the cells by adding a buffer which is hypotonic or comprises detergent, and contains an inhibitor of DNAase; removal of RNA from the cell lysate with ribonuclease; centrifugation of the first set of receivers at low speed; transfer of a supernatant containing DNA fragments to the second set of receivers; adding a detectable compound capable of intercalation with DNA fragments in a buffer for detection containing DNAase inhibitor to at least one receiver; measuring the amount of intercalated detectable compound; and comparing the amount of intercalated detectable compound to the control for determining the difference that enables to identify the said agent as a modifying agent if the difference exceeds a predetermined limit.
EFFECT: invention enables to detect agents that affect the formation of DNA fragments in cells using high performance screening applications.
10 cl, 14 dwg, 2 tbl, 11 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOSITION AND METHOD OF TUMOUR CURING | 2007 |
|
RU2500815C2 |
SYNTHETIC LETHALITY AND TREATMENT OF CANCER | 2013 |
|
RU2676697C2 |
AGENT WITH ANTIAPOPTOTIC ACTIVITY | 2018 |
|
RU2685428C1 |
HUMANISED MONOCLONAL ANTIBODY SPECIFIC FOR LEGUMAIN | 2013 |
|
RU2574203C2 |
ANTAGONIST-LIGAND RAR-γ OR AGONIST-LIGAND RAR-α AS INHIBITOR OF APOPTOSIS | 1996 |
|
RU2191008C2 |
METHOD OF ISOLATION OF HIGH-MOLECULAR PROTEIN ACTIVATION COMPLEX OF HUMAN CASPASE-2 | 2016 |
|
RU2671510C1 |
COMPOSITION AND METHOD FOR TREATMENT OF EYE DISEASE ASSICIATED WITH NUCLEIC ACIDS | 2012 |
|
RU2642609C2 |
HYBRIDOMA DESIGNATES AS 199M AND MONOCLONAL ANTIBODY SECRETED BY THIS HYBRIDOMA | 1997 |
|
RU2183671C2 |
AGENT STIMULATING APOPTOSIS OF HUMAN LEUKAEMIA CELLS | 2007 |
|
RU2360692C1 |
COMBINATION OF ANTIBODY HAVING SELECTIVITY IN RELATES TO APOPTOSIS INDUCING LIGAND RECEPTOR ASSOCIATED WITH TUMOR NECROSIS FACTOR AND OTHER THERAPEUTIC AGENTS | 2002 |
|
RU2313368C2 |
Authors
Dates
2013-06-27—Published
2007-06-20—Filed